Unicycive Therapeutics Stock (NASDAQ: UNCY)

Dernières nouvelles pour Unicycive Therapeutics (NASDAQ:UNCY) Stock

UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics Inc

WIIM

CIVI

Civitas Resources shares are trading higher after UBS raised its price target on the stock from $27 to $30.

Canaccord Genuity and Needham analysts initiate coverage of Omada Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Buy rating.
<ul class="wp-block-list">
<li>Canaccord Genuity <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8cb85e9300015f1adb/richard-close">analyst Richard Close</a> assigns a price target of $27.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58aed4dab85e9300013bf4d1/ryan-macdonald">analyst Ryan MacDonald</a> assigns a price target of $23.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Canaccord Genuity: Omada&#8217;s AI virtual care platform is "differentiated in a competitive chronic-care market," Close said in his initiation note. The company also has an &#8220;impressive&#8221; financial profile, he added.
"This is especially true with respect to gross margins, exemplified by adj-GPM reaching 69.4% in 4Q&#8217;24 and 60.3% in 1Q&#8217;25," the analyst wrote. The stock trading about 4% below its IPO price offers "a very interesting opportunity," he further stated.
Needham: Backed by its virtual-first care platform, Omada is rapidly gaining market share at the cost of legacy incumbents, MacDonald said in his initiation note. Rising healthcare costs due to chronic conditions have driven employers to look for coverage alternatives, he added.
Omada's business is poised to generate over 35% growth while approaching adjusted EBITDA breakeven, driven by "GLP-1 success, improving cross-sell and expanding PBM relationships," the analyst stated.
Price Action: Shares of Omada Health declined by 1.26% to $18.07 at the time of publication on Tuesday.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in">Hinge Health&#8217;s Tech Is Primed To Capture America&#8217;s Untapped MSK Pain Market: Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Initiation

IPOs

Analyst Ratings

OMDA

Omada Health Analysts Say 'Buy' — While It's Still Below IPO Price

Led by Professor Lisa Horvath, from Sydney's Chris O'Brien Lifehouse, and ANZUP, the innovative 60-participant placebo-controlled randomized study is designed to test the potentially enhancing effect of opaganib in overcoming resistance to standard of care androgen receptor pathway inhibition (ARPI) treatment.
The unique study will utilize a companion lipid biomarker test (PCPro5) to select&nbsp;mCRPC patients who have poor prognosis to standard of care treatment, and who may benefit from an opaganib + darolutamide combination approach to treatment. The study's primary endpoint is improved 12-month radiographic progression-free survival (rPFS). Several secondary and exploratory endpoints will also be evaluated.

Biotech

News

General

RDHL

RedHill Biopharma Announces The Initiation Of Patient Recruitment Into The Phase 2 Study Evaluating The Efficacy Of Opaganib3 In Combination With Darolutamide4 In Men With Metastatic Castrate-Resistant Prostate Cancer

Ryder System shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform. Additionally, Baird reinstated an Outperform rating on the stock and announced a price target of $186.

Small and medium-sized businesses (SMBs) are often tasked with making quick, informed decisions that can mean the difference between growth and stagnation. However, many SMB owners still rely on fragmented financial systems to manage their operations, often to their detriment.&nbsp;
In fact, many SMB owners admit that cash-flow blind spots and manual processes lead to delayed decisions, resulting in missed opportunities and increased operational risk. This is where unified finance platforms provide a timely solution.&nbsp;
Integrating banking, bookkeeping, payments, and forecasting into one unified platform gives SMB owners real-time insight and greater credibility with lenders. These tools provide a transformative edge in an uncertain economy that SMB owners must capitalize on.
<h2 class="wp-block-heading">The Cost of Fragmented Finance Data</h2>
For many SMBs, the financial back office can be a maze of spreadsheets, siloed software, and manual data entry. As a result, reconciling accounts across multiple systems isn&#8217;t just tedious, it&#8217;s a risky process.&nbsp;
Realistically, small‑business owners spend an average of 16 hours a week reconciling bank, bookkeeping, and payment data &#8211; two full working days that never touch sales or strategy.&nbsp;
These inefficiencies are especially dangerous in the current economic climate, where interest rates remain high, input costs fluctuate, and supply chain volatility continues. In this environment, financial missteps due to fragmented data can quickly compound into major setbacks.
In addition, when liquidity is unclear, owners are forced to postpone hiring, delay purchasing inventory, and slip past lender deadlines. In a rate environment that has swung between <a href="https://www.statista.com/statistics/187616/effective-rate-of-us-federal-funds-monthly/">4% and 6%</a> since early 2024, every indecision carries a hefty price.
<h2 class="wp-block-heading">What a Unified Finance Platform Looks Like</h2>
A <a href="https://www.benzinga.com/opinion/23/06/32975306/transforming-finance-the-power-of-unified-communications-and-collaboration">unified finance</a> platform merges key financial operations into a single dashboard, often built with modular tools and real-time data syncs. At its core, such a system includes:
<ul class="wp-block-list">
<li>Real-time Bank Feeds: Instant synchronization with financial institutions.</li>
<li>General Ledger Integration: Seamless bookkeeping and reconciliations.</li>
<li>Accounts Payable/Receivable: Automated payment cycles and collections.</li>
<li>Rolling Forecasts: Continuous forward-looking cash flow visibility.</li>
</ul>
These platforms offer SMBs an intuitive interface that simplifies financial management, from daily cash flow tracking to long-term forecasting. The result is a more cohesive view of the business's financial health without the need to switch between multiple tools.&nbsp;
Some of the top providers of these platforms include:
<ul class="wp-block-list">
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) – Known for QuickBooks, offering real-time bank feeds, invoicing, and financial reporting.</li>
<li>Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) – Provides comprehensive accounting and finance solutions with integrated data management tools.</li>
<li>Xero Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XROLF#OTC">XROLF</a>) – Offers cloud-based accounting software with easy integration and automatic bank reconciliation.</li>
</ul>
<h2 class="wp-block-heading">Three Tangible Wins for SMB Leaders</h2>
Unified finance platforms give SMBs various advantages that help streamline operations, refine financial processes, and improve administrative efficiency. Let's take a look at the three major areas where SMBs can win big with unified finance platforms:
<h3 class="wp-block-heading">Win #1: Same-Day Visibility</h3>
SMBs using unified finance platforms often reclaim 20 to 25 hours per week previously spent on manual finance tasks. In fact, businesses can reduce time spent on tasks by as much as 40% when they <a href="https://lavu.com/how-to-automate-payroll-with-pos-systems/">automate financial processes</a>. This same-day visibility allows business owners to spot anomalies, approve payments, and make spending decisions without delay.
<h3 class="wp-block-heading">Win #2: Forward-Looking Cash Intelligence</h3>
Traditional finance systems often focus on historical data. Unified platforms change that by enabling 13-week rolling forecasts that anticipate cash gaps or surplus periods. Using these insights, SMBs can proactively adjust hiring plans, negotiate supplier terms, or time strategic investments, with some businesses seeing <a href="https://www.linkedin.com/pulse/business-case-automated-reconciliation-software-roi-benefits-koshai-ry1jc/">returns on investment (ROI) rise 60%</a> in just one year.
<h3 class="wp-block-heading">Win #3: Better Lender Terms</h3>
When SMBs can present real-time cash flow reports and automated ledgers, lenders take notice. For SMBs with integrated finance systems, underwriting becomes up to 31% faster, and risk assessment accuracy increases by 43%. These systemic improvements can make SMBs considerably more trustworthy to lenders, offering quicker loans at more favourable rates.
These three tangible wins demonstrate how unified finance platforms create clear advantages for SMB leaders. By streamlining financial management, business owners can make quicker decisions, optimize their cash flow with confidence, and attract better terms for term loans, <a href="https://finturf.com/">POS financing</a>, and other lending avenues.
<h2 class="wp-block-heading">Implementing a Unified Platform: Owner Checklist</h2>
For SMB owners considering transitioning to a unified finance platform, here's a checklist to guide the implementation process:
<ul class="wp-block-list">
<li>API Coverage: Ensure the platform integrates with your bank, payroll, and other essential business tools.</li>
<li>SOC 2 Type II Security: Choose a platform that offers robust security to protect sensitive financial data.</li>
<li>13-Week Forecasting: Verify that the platform provides a rolling forecast feature for cash flow management.</li>
<li>ROI Horizon: Calculate the expected ROI for implementing the platform.</li>
<li>Change-Management Plan: Develop a plan for training your team and adapting to the new platform.</li>
</ul>
By following this checklist, SMB owners can set themselves up for success when implementing a unified finance platform. Proper planning ensures that the transition is smooth, the platform integrates seamlessly with existing tools, and delivers the expected benefits, including streamlined operations, enhanced cash flow management, and improved decision-making.
<h2 class="wp-block-heading">Conclusion</h2>
Fragmented ledgers once forced SMB leaders to choose between accuracy and speed. Today, unified finance platforms have removed that dilemma. With cash visibility consolidated, forecasts automated, and documents audit‑ready, owners spend fewer hours on reconciliation and more on growth.
As SMBs navigate uncertainty, real-time visibility and data integration enable smarter, faster decision-making. Whether it's securing better loan terms, anticipating cash flow issues, or saving staff hours, the benefits are clear.&nbsp;
For SMB leaders, the future of financial decision-making is unified and data-driven.

Fintech news covering the emerging Financial Technology services sector

Fintech

Opinion

INTU

ORCL

XROLF

How Unified Finance Platforms Improve SMB Decision Making

Macro Economic Events

Econ #s

Economics

Breaking: Senate Voting on Trump's "Big Beautiful Bill"

JP Morgan analyst Anthony Elian maintains Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) with a Neutral and raises the price target from $15 to $16.

Price Target

BANC

JP Morgan Maintains Neutral on Banc of California, Raises Price Target to $16

Susquehanna analyst Charles Minervino maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $40 to $46.

Susquehanna Maintains Neutral on Valaris, Raises Price Target to $46

If you got a bonus at work, Kevin O'Leary wants you to pause before spending it. The investor and TV personality says the worst thing you can do is waste that money on something &#8220;frivolous and useless.&#8221;
<h2 class="wp-block-heading">O'Leary's Bonus Rule: Use It To Eliminate Debt</h2>
In a recent video <a href="https://x.com/kevinolearytv/status/1938964353320903109">posted on X</a>, O'Leary said, &#8220;The temptation is to go buy something frivolous and useless. That's a waste of money. The discipline is to do this: <a href="https://www.benzinga.com/money/best-ways-to-pay-off-credit-card-debt">Pay off your credit card debt</a>. Anything left over, knock a little bit off your mortgage.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
O'Leary&#8217;s core message is simple: Use your bonus to get rid of debt. &#8220;You want a real bonus in life? <a href="https://www.benzinga.com/personal-finance/25/02/43816145/i-dont-have-any-debt-kevin-oleary-pays-for-everything-in-cash-but-a-finance-youtuber-points-out-its-easy-to-avoid-debt-when-youre-rich">Live it debt-free</a>. That's a bonus. That's why you use your bonus to get [there],&#8221; he said.
His advice lines up with what many personal finance experts recommend when you come into extra money, whether it&#8217;s from a bonus, inheritance, <a href="https://www.benzinga.com/personal-finance/entrepreneurship/25/06/46026335/from-side-hustle-to-big-business-young-entrepreneur-makes-354000-a-month">side hustle</a> or tax refund.
<h2 class="wp-block-heading">What To Do With Extra Money</h2>
The first step is to <a href="https://www.benzinga.com/money/what-to-do-with-savings">eliminate high-interest debt</a>, especially credit card balances that can come with rates up to 27%. This is a common recommendation from personal finance experts like Dave Ramsey, who emphasize paying off debt before making any major financial moves. Investing usually won't generate returns that high, so paying off debt can be a smarter move.
Next, focus on building an emergency fund that can cover three to six months of living expenses. Stash it in a <a href="https://www.benzinga.com/money/best-high-yield-savings-accounts">high-yield savings</a> or money market account.
Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
If you own a home and your mortgage rate is above 4%, <a href="https://www.benzinga.com/money/how-to-lower-your-mortgage-payment">putting extra money toward your principal</a> can reduce interest over the life of the loan and shorten your repayment timeline.
Once you&#8217;re on solid footing, consider increasing your retirement contributions, starting or adding to a health savings account, or <a href="https://www.benzinga.com/money/best-529-plans">putting money into a 529 plan</a> for education savings.
Other smart moves include <a href="https://www.benzinga.com/money/open-brokerage-account">starting a brokerage account</a>, <a href="https://www.benzinga.com/money/how-to-invest-in-real-estate">investing in real estate</a>, <a href="https://www.benzinga.com/personal-finance/24/10/41285154/mark-cuban-says-if-youre-starting-a-business-and-you-take-out-a-loan-youre-a-moron-99-of-small-b">launching a business</a>, or saving for a big future purchase.
And yes, it's perfectly fine to spend a little on yourself, just don't let that come before taking care of your financial foundation.
Still, O'Leary's bottom line remains straightforward: using your bonus to eliminate debt offers the most long-term value. &#8220;Getting rid of debt is the key thing,&#8221; he said.
Read Next:
<ul class="wp-block-list">
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Image: Shutterstock

Personal Finance

Kevin O'Leary Says If You Got A Bonus, Don't Blow It. Pay Off Your Debt, Kill Your Credit Cards, And Chase Freedom By Living Debt-Free

Susquehanna analyst Bascome Majors maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Positive and lowers the price target from $46 to $44.

Susquehanna Maintains Positive on Schlumberger, Lowers Price Target to $44

Texas Instruments's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NYSE">TXN</a>) short percent of float has fallen 12.71% since its last report. The company recently reported that it has 16.83 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Texas Instruments Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Texas Instruments has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Texas Instruments's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Texas Instruments's peer group average for short interest as a percentage of float is 5.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Texas Instruments's Recent Short Interest

SolarEdge Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NYSE">SEDG</a>) short percent of float has fallen 12.33% since its last report. The company recently reported that it has 15.92 million shares sold short, which is 31.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SolarEdge Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SolarEdge Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SolarEdge Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SolarEdge Technologies's peer group average for short interest as a percentage of float is 7.71%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SEDG

How Do Investors Really Feel About SolarEdge Technologies?

Blue Owl Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) short percent of float has risen 28.81% since its last report. The company recently reported that it has 37.75 million shares sold short, which is 6.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Blue Owl Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751385615_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Blue Owl Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Blue Owl Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Blue Owl Capital's peer group average for short interest as a percentage of float is 3.50%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Blue Owl Capital?

Susquehanna analyst Charles Minervino maintains Oil States International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) with a Neutral and raises the price target from $4.5 to $5.5.

Susquehanna Maintains Neutral on Oil States International, Raises Price Target to $5.5

JP Morgan analyst Destiny Jackson initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Overweight rating and announces Price Target of $20.

JP Morgan Initiates Coverage On Omada Health with Overweight Rating, Announces Price Target of $20

<a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1082425</a>

MBIO

Mustang Bio Receives FDA Orphan Drug Designation For MB-101 Treatment Of Malignant Glioma

Mustang Bio Designated Orphan Designation Status For "an autologous ex vivo expanded cluster of differentiation 62-enriched naive and memory T-cell investigational product that has been genetically modified using a self-inactivating lentiviral vector to express an IL13Ralpha2-targeted, hinge-optimized, 4-1BB-costimulatory chimeric antigen receptor with a truncated CD19" For The Treatment Of Malignant Glioma

HUBG

Hub Group shares are trading higher after Baird reinstated an Outperform rating on the stock and announced a price target of $44.

Susquehanna analyst Charles Minervino maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Positive and lowers the price target from $19 to $18.

Susquehanna Maintains Positive on NOV, Lowers Price Target to $18

Susquehanna analyst Charles Minervino maintains Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) with a Neutral and raises the price target from $25 to $30.

Susquehanna Maintains Neutral on Noble Corp, Raises Price Target to $30

Earnings

Press Releases

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Health Care

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

Unicycive Therapeutics to Present at Upcoming Investor Conferences

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Comments

Unicycive Therapeutics

Actualités

Dernières nouvelles pour Unicycive Therapeutics (NASDAQ:UNCY) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL